enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

1.580 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about enGene Therapeutics Inc. - Common Stock

< Previous 1 2 Next >

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path ↗

October 16, 2026

enGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse,...

Via MarketBeat

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market ↗

August 13, 2026

enGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a...

Via MarketBeat

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗

May 30, 2026

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

Via The Motley Fool

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗

May 30, 2026

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

Via The Motley Fool

Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗

May 15, 2026

Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.

Via The Motley Fool

Topics Regulatory Compliance

Unusual volume stocks are being observed in Monday's session. ↗

May 11, 2026

Via Chartmill

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain ↗

May 08, 2026

enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk...

Via MarketBeat

Which stocks are experiencing notable movement on Thursday? ↗

May 07, 2026

Via Chartmill

Top stock movements in today's session. ↗

May 07, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

May 07, 2026

Via Chartmill

Which stocks are moving before the opening bell on Thursday? ↗

May 07, 2026

Via Chartmill

This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗

March 21, 2026

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗

November 11, 2025

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

November 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗

November 11, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 11, 2025

Via Benzinga

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial ↗

November 11, 2025

enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 11, 2025

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗

November 11, 2025

Via Benzinga

ENGN Stock Soars On Hopeful Data From Bladder Cancer Study ↗

November 11, 2025

The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026.

Via Stocktwits

Get insights into the top gainers and losers of Tuesday's pre-market session. ↗

November 11, 2025

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Via Chartmill

enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles ↗

September 11, 2025

enGene posts wider-than-expected Q3 loss as R&D spending doubles. The biotech advances its pivotal LEGEND trial and secures key FDA RMAT designation.

Via Chartmill

enGene Posts 78% Expense Jump in Q3 ↗

September 11, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 28, 2025

Via Benzinga

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

February 18, 2025

Via Benzinga

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

November 18, 2024

Via Benzinga

Why enGene Holdings Stock Is Trading Higher ↗

October 25, 2024

enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement.

Via Benzinga

IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 24, 2024

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.